ResearcherFujian Medical UniversityActive in the last 2 years
Jieming Xie
Matched on ORCID iD 0000-0003-3884-0550; OpenAlex author ID A5101479004. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 11
2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 7
- Retraction Note: MiR-221 inhibits proliferation of pancreatic cancer cells via down regulation of SOCS3. Co-author DOI 10.26355/eurrev_202403_35572↗
- Gemcitabine-Resistance Reversion of Cucurmosin in Human Pancreatic Cancer Cells Last author DOI 10.21203/rs.3.rs-722308/v1↗
- Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolomic study. Co-author DOI 10.21037/gs-20-202↗
- Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression. Last author DOI 10.3892/or.2014.3599↗
- PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug. Last author DOI 10.1097/mpa.0000000000000087↗
- Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathway. Co-author DOI 10.1016/s1734-1140(13)71046-6↗
- Cucurmosin kills human pancreatic cancer SW-1990 cells in vitro and in vivo. Co-author DOI 10.2174/18715206113139990109↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Congfei Wang · 6 shared papers, 2013–2021 · strength 0.49
- Paper Gemcitabine-Resistance Reversion of Cucurmosin in Human Pancreatic Cancer Cells DOI 10.21203/rs.3.rs-722308/v1↗
- Paper Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolom… DOI 10.21037/gs-20-202↗
- Paper Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression. DOI 10.3892/or.2014.3599↗
- Cheng Hh · 1 shared paper, 2024 · strength 0.26
- Minghuang Chen · 4 shared papers, 2013–2020 · strength 0.24
- Paper Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolom… DOI 10.21037/gs-20-202↗
- Paper PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor r… DOI 10.1097/mpa.0000000000000087↗
- Paper Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathwa… DOI 10.1016/s1734-1140(13)71046-6↗
- Heguang Huang · 2 shared papers, 2013–2021 · strength 0.23
- Heguang Huang · 3 shared papers, 2013–2015 · strength 0.15
- Paper Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression. DOI 10.3892/or.2014.3599↗
- Paper PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor r… DOI 10.1097/mpa.0000000000000087↗
- Paper Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathwa… DOI 10.1016/s1734-1140(13)71046-6↗
- Tianhong Teng · 1 shared paper, 2020 · strength 0.11
- Heguang Huang · 1 shared paper, 2020 · strength 0.11
- Pengfei Guo · 1 shared paper, 2020 · strength 0.11
- Binbin Wei · 1 shared paper, 2020 · strength 0.11
- Jianghua Feng · 1 shared paper, 2020 · strength 0.11
- Weiwei Zhang · 1 shared paper, 2015 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.